PharmaLytica expo to be held in hybrid mode
The webinar and in-person expo on Aug 13, 14 will take up issues such as dependence on China for key APIs among others
image for illustrative purpose
Hyderabad: Informa Markets, a B2B event organiser, will conduct PharmaLytica 2021, an exhibition of leading pharma companies in the hybrid format, that is, in person and virtual. The live in-person event will be held on August 13 and 14 at the Hitex exhibition centre, Hyderabad and the online event from from August 13 to 20, according to the organiser.
The expo will bring together world's leading pharmaceutical companies, eminent speakers, a knowledge forum and networking opportunities, under a hybrid ecosystem for the first time since its inception. It will be attended by leading pharmaceutical companies that cater to markets such as pharmaceutical ingredients, pharma machinery and packaging, laboratory services and analytical services.
The expo comes at a timely moment with the domain facing a transformation. Dependence on China for key Active Pharmaceutical Ingredient (APIs) has been an ongoing concern for the industry, affecting crucial raw materials for manufacturing medicines for cardio-vascular, diabetes, antibiotics, anti-allergic and vitamins. The pharma industry needs to be in a state of continuous, steady improvement, to spur medical advances, and as the life sciences industry evolves, advancements in lab equipment too will see a boost.
Yogesh Mudras, Managing Director, Informa Markets in India, said: "This year we bring to you PharmaLytica in a hybrid avatar, making the most of the online as well as offlineinterfaces. Its 7th edition will continue the legacy of being the leading marketplace for productsand services such as lab and analytical equipment to pharma packaging solutions and pharmamachinery. The two-day physical expo and its virtual edition are as timely as it is relevant, especially in this ongoing pandemic. As the world raced to develop drugs and vaccines to tacklethe novel coronavirus, significant investments have been made to upgrade lab infrastructureand equipment to aid and accelerate R&D efforts by private players and governments. India'slab equipment market will also see an upsurge due to government initiatives, to make India's pharma Inc stronger and self-sustaining, increasing funding for life sciences and development ofclinical capabilities."
